View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 3, 2020

ASCO 2020: The shifting paradigm in drug development: from tissue specific to tumour-agnostic

By Victoria Smith

Clinical ontology development has traditionally targeted cancer-dependent target identification; over the past two decades, a number of therapeutic modalities have been designed to target a vast array of molecular signatures in cancer. Elucidation of the genetic landscape of tissue-specific cancers allowed the establishment of mutation-specific targeted treatments, allowing realistic aspiration for targeted therapies customised to the particular genetic aberrations found in a patient’s tumour.

Earlier this year at ASCO 2020 exposed a shift away from this paradigm, particularly for targeting rare cancers, from tissue-specific to tissue-agnostic drug development. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology